Differences In Vascular Endothelial Growth Factor Research Articles

Efficacy and safety of the combination of paclitaxel, cisplatin and bevacizumab for the treatment of non-small cell lung cancer

Purpose: To investigate the efficacy and safety of the combined use of paclitaxel, cisplatin, and bevacizumab for the treatment of non-small cell lung cancer (NSCLC). Methods: 98 NSCLC patients who received therapy at Hainan Hospital of Traditional Chinese Medicine, Changsha, China from January 2018 to December 2022 were retrospectively analyzed. The 45 patients who received paclitaxel and cisplatin injections were enrolled in a control group while 53 patients who received additional chemotherapy with bevacizumab injection were enrolled in a study group. Levels of vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) were compared before and after treatment. Furthermore, the efficacy and incidence of adverse reactions were evaluated and compared between the two groups. Results: There was no significant inter-group difference in VEGF and bFGF levels (p > 0.05) before treatment. There was a significant reduction in VEGF and bFGF levels in the study group compared to control group (p < 0.05). The study group showed a significantly higher total remission rate compared to control group (p < 0.05). Furthermore, there was no significant difference in the incidence of adverse reactions between the two groups (p > 0.05). Also, age, tumor, node, metastasis (TNM) stage, metastasis, and smoking history are risk factors that influence patient prognosis. Conclusion: Combination of paclitaxel, cisplatin and bevacizumab demonstrates significant efficacy in the treatment of NSCLC. The combination lowers VEGF and bFGF levels without worsening adverse reactions. Future large population studies would be required to obtain a more detailed and comprehensive outcome on this combination in NSCLC.

Evaluation of the 18-bp deletion/insertion variant of the VEGF gene in athletes

The skeletal muscle capillary supply mainly determines the highest exercise capacity. Vascular endothelial growth factor (VEGF) is the major growth factor during the angiogenesis process. Therefore, we aimed to investigate whether the VEGF insertion/deletion (I/D) variant differs between athletes and sedentary controls in the Turkish population. Three hundred sixteen subjects, including 146 athletes from different branches and 170 sedentary people, voluntarily participated in this study. Genomic DNA was isolated and genotyped using polymerase chain reaction (PCR) analysis for the VEGF I/D variant. The results were evaluated statistically. In this study, the athletes and the controls showed a statistically significant difference in the genotype and allele distribution of the VEGF I/D variant. The athletes had a more prevalent D allele and D/D genotype than the controls (p = 0.008 and p = 0.034, respectively). There was a statistically significant association between the patients and the controls in terms of D/D vs. I/I + I/D genotypes (p = 0.018). There was no significant difference in VEGF I/D genotype distribution according to sports branches. Athletic performance is a complex trait influenced by genetic and environmental factors. As far as we know, this is the first study to evaluate the VEGF I/D variant in athletes in Turkey. According to our results in this study, we concluded that the VEGF I/D variant, D/D genotype, and D allele are associated with sport performance in the Turkish population. However, there is a need for studies with large samples in which environmental and emotional factors will also be taken into account.

Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation

BackgroundEvidence indicates that vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) influence the pathophysiology of depression. However, whether low-dose ketamine regulates VEGF and MMP-9 levels and whether changes in VEGF and MMP-9 levels are associated with the antidepressant and antisuicidal effects of ketamine remained unclear. MethodsForty-eight patients with treatment-resistant depression and strong suicidal ideation (TRD-SI) were randomly assigned to a single infusion of 0.5-mg/kg ketamine or 0.045-mg/kg midazolam. The Montgomery–Åsberg Depression Rating Scale (MADRS) and Columbia-Suicide Severity Rating Scale–Ideation Severity Subscale (CSSRS-ISS) were used at baseline and subsequently at several postinfusion timepoints. VEGF and MMP-9 serum levels were analyzed at baseline and on day 3 postinfusion. ResultsAfter adjustment for baseline levels, no significant differences in VEGF (p = .912) and MMP-9 (p = .758) levels were identified on day 3 postinfusion between the study groups. Baseline VEGF levels but not MMP-9 levels were negatively associated with MADRS and CSSRS-ISS scores following infusion. DiscussionA single infusion of low-dose ketamine did not alter the VEGF and MMP-9 levels of the patients with TRD-SI. Higher baseline VEGF levels were associated with greater antidepressant and antisuicidal effects of single low-dose ketamine infusion.

Is the Long‐term Impact of a Multidomain Lifestyle Intervention on Cognitive Function Mediated by Changes in Leptin and Vascular Endothelial Growth Factor Concentrations?

AbstractBackgroundThe 10‐year intensive lifestyle intervention (ILI) of the Look AHEAD study resulted in a legacy of relative deficits in cognitive function among participants who entered the clinical trial with a history of cardiovascular disease or current obesity, as compared to participants assigned to the diabetes support and education (DSE) intervention. We hypothesized that levels of two weight‐sensitive proangiogenic cytokines, leptin and vascular endothelial growth factor (VEGF), which have been previously reported to be associated with cognitive function, may have been altered by the ILI and account for this concerning finding.MethodConcentrations of leptin and VEGF were determined using stored serum collected from 1,279 participants at Look AHEAD baseline, proximal to cessation of the intervention (Epoch 1), and an average of 4 years later (Epoch 2). Masked clinic staff conducted up to four standardized assessments of cognitive function at times ranging from 8 to 18 years after baseline. A composite score was derived from tests of attention, executive function, and memory. Mixed effects models were used to assess relative differences in leptin and VEGF concentrations between intervention groups and whether these accounted for changes in cognitive composite scores, overall and within subgroups defined by baseline history of cardiovascular disease or obesity.ResultIn both intervention groups, leptin concentrations increased from baseline to Epoch 1, and further between Epochs 1 and 2 (p<0.001). VEGF concentrations decreased between enrollment and Epoch 2 in both groups, and decreased substantially more between Epoch 1 and 2 in ILI than in DSE (p = 0.04). Overall, there was little evidence that leptin and VEGF concentrations were related to cognitive functioning. ILI‐DSE differences in VEGF, but not leptin, concentrations varied depending on baseline history of cardiovascular disease and obesity, but neither leptin or VEGF concentrations accounted for the relative decrements in cognitive function evident during long‐term follow‐up in participants assigned to ILI.ConclusionAmong persons with type 2 diabetes and either a history of cardiovascular disease or obesity, long‐term relative deficits in cognitive function associated with intensive lifestyle intervention are not related to differences in two weight‐sensitive proangiogenic cytokines.

Association of polymorphisms of VEGF and VEGFR1 pathways related genes and risk of pre-eclampsia

To assess the association of single nucleotide polymorphisms (SNPs) of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 1 (VEGFR1) pathways-related genes and the risk of pre-eclampsia. In total 178 pregnant women with pre-eclampsia (case group) and 100 healthy pregnant women (control group) during the third trimester were enrolled. The SNPs of VEGF rs3025039, rs2010963 and VEGFR1 rs3812867, rs55875014 and rs722503 loci were determined by PCR-restriction fragment length polymorphism (PCR-RFLP) assay. The levels of serum VEGF and sVEGFR1 were also determined. And their association with pre-eclampsia was analyzed. The systolic blood pressure, diastolic blood pressure and sVEGFR1 of the case group were significantly higher than those of the control group, while the VEGF level was significantly lower than that in the control group (P<0.05). Allelic frequencies of the VEGF (rs3025039, rs2010963) and VEGFR1 (rs3812867, rs55875014, rs722503) have fit the Hardy-Weinberg equilibrium (P>0.05). The frequency of T allele of VEGF at rs3025039 locus in the case group was higher than that in the control group (P<0.05). There were significant differences in VEGF at rs3025039 locus under dominant and co-dominant models in case group (P<0.05). Compared with those with CC, the risk was higher in patients with CT or TT genotypes (P<0.05). The systolic and diastolic blood pressure and sVEGFR1 in pre-eclampsia pregnant women with CT or TT genotypes were significantly higher than those with the CC genotype, while their VEGF level was significantly lower (P<0.05). No significant difference was found in allelic frequencies of other four loci between the two groups (P>0.05). Polymorphisms of rs3025039 locus of VEGF gene is associated with the occurrence of pre-eclampsia. The variant at this locus may affect the activity of VEGF and influence the development of pre-eclampsia.

Predictors of anti-VEGF efficacy in chronic central serous chorioretinopathy based on intraocular cytokine levels and pigment epithelium detachment subtypes.

The aim of this study was to compare intraocular cytokines among different types of pigment epithelial detachments (PEDs) in patients with chronic central serous chorioretinopathy (CSC) and to investigate the association of cytokine levels and PED types with response to anti-vascular endothelial growth factor (VEGF) therapy. We included 88 patients with chronic CSC and 30 controls. The anti-VEGF agent conbercept was given intravitreally to chronic CSC patients. Cytokines VEGF, interleukin-6 (IL-6), IL-8, IL-10, interferon-inducible protein-10 and monocyte chemoattractant protein-1 in aqueous humour were measured. Treatment efficacy, cytokine levels, changes in best-corrected visual acuity (BCVA) and optical coherence tomography parameters were assessed at baseline and 1 month after treatment. Patients were divided into three groups: flat irregular PED (FIPED) with choroidal neovascularization (CNV), FIPED without CNV and focal PED. Vascular endothelial growth factor (VEGF) was the only cytokine significantly higher in chronic CSC FIPED patients. There were no significant differences in VEGF between FIPED patients with or without CNV (p = 0.234). At 1 month after conbercept injection, treatment effective rates in FIPED patients with or without CNV were significantly higher than in patients with focal PED (p < 0.05). Best-corrected visual acuity (BCVA) was improved in both FIPED groups (p < 0.05), but not in the focal PED group (p = 0.180). All three groups had significant decreases in central macular thickness (p < 0.05), and PED heights in FIPED patients were reduced (p < 0.05). Patients with FIPED in chronic CSC had elevated intraocular VEGF levels and responded favourably to conbercept. Anti-VEGF treatment may be an option for FIPED CSC patients with or without secondary CNV.

Dimethylarginine dimethylaminohydrolase-1 contributes to exercise-induced cardiac angiogenesis in mice.

Dimethylarginine dimethylaminohydrolase-1 (DDAH1) maintains nitric oxide (NO) bioavailability by degrading asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS). It has been well established that DDAH1 and exercise play crucial roles in promoting cardiac angiogenesis under pathological conditions. However, the role of DDAH1 in exercise-induced cardiac angiogenesis remains unclear. In this study, we focused on the change in DDAH1 in response to moderate exercise and the underlying mechanism of exercise-induced cardiac angiogenesis. Eight-week-old male DDAH1 global knockout (KO) mice and DDAH1flox/flox mice (wild-type) were randomly divided into sedentary groups (control) and swimming groups (exercise). After eight weeks of swimming at five days per week, all the mice were anesthetized and sacrificed. Histological examination and Western blot analysis were performed. There were low levels of myocardial capillaries in DDAH1 KO mice under control and exercise conditions. Notably, exercise elevated DDAH1 protein expression, as observed by Western blot analysis. The common cardiac angiogenesis biomarkers vascular endothelial growth factor (VEGF) and Caveolin-1 were increased during exercise. A significant difference in VEGF was observed between the DDAH1 KO and wild-type groups. Similarly, increased Caveolin-1 expression was abrogated in DDAH1 KO mice. Furthermore, we tested the R-Ras/AKT/GSK3β signaling pathway to study the underlying molecular mechanism. DDAH1 may regulate the R-Ras/AKT/GSK3β pathway due to distinct protein changes in this pathway in the DDAH1 KO and wild-type groups. Our findings suggest that DDAH1 plays an important role in exercise-induced cardiac angiogenesis by regulating the R-Ras/AKT/GSK3βsignaling pathway.

Dysregulation of the Angiopoietin-2/Tie-2 Axis is Associated with Reduced Pulsatility and Increased Arteriovenous Malformation Related Gastrointestinal Bleeding Following Left Ventricular Assist Device Implantation

Recent studies have suggested arteriovenous malformation related gastrointestinal bleeding (AVM-GIB) after left ventricular assist device (LVAD) implantation is associated with reduced arterial pulsatility and right heart failure. Angiopoietin-2 (Ang-2) is elevated among patients on LVAD support, and in concert with abnormal expression of vascular endothelial growth factor (VEGF), binding of Ang-2 to the Tie-2 receptor contributes to abnormal angiogenesis and post-LVAD GIB. The purpose of this study was to evaluate the association between Ang-2, Tie-2, and VEGF with AVM-GIB and its clinical associates. We evaluated 65 patients who underwent LVAD implantation at Loyola University Medical Center. Blood samples were obtained at a median follow up of 13 (interquartile range 1.7-31.5) months following LVAD implantation. A total of 19 (29%) patients developed AVM-GIB. Patients with AVM-GIB were older at the time of LVAD implantation (63±10 vs. 53±15 years; p=0.048), but the groups were otherwise balanced in baseline characteristics. Patients with AVM-GIB had increased levels of Ang-2 (8169±4.471 vs. 6560±397 pg/mL; p=0.02) and Tie-2 (20.0±3.3 vs. 17.3±4.0 ng/mL; p=0.07) without a difference in VEGF (200.5±183.3 vs. 216.6±220 pg/mL; p=0.7). Patients whose aortic valve opened less than 80% of cardiac cycles had significantly higher levels of Ang-2 (7948±4226 vs 5566±3691 pg/mL; p=0.02) and Tie-2 (19.6±4.5 vs. 16.3±3.2 ng/mL; p=0.001). There was no association between the evaluated biomarkers and other demographic or clinical characteristics including invasive and noninvasive hemodynamics. Our study suggests that dysregulation of the Ang-2/Tie-2 axis among LVAD patients is associated with AVM-GIB. Further, we find that reduced pulsatility is associated with elevations of Ang-2 and Tie-2, providing a possible mechanism for the link between reduced pulsatility and GIB. Whether hemodynamic optimization with ramp studies could reduce Ang-2 and AVM-GIB is a subject of our ongoing research.

The Difference of Endometrial Vascular Endothelial Growth Factor (VEGF) Expression between Polycystic Ovarian Syndrome (PCOS) and Normal Women

Background: Polycystic Ovarian Syndrome (PCOS) is an endocrine disorder in women cha­rac­terized by increased levels of androgens, ovu­la­tory dysfunction, and Polycystic Ovarian Mor­p­ho­logy (PCOM), as well as a combination of clas­sic clinical features. Women with PCOS expe­ri­ence changes in the endometrium and endo­met­rial receptivity markers such as VEGF (Vascular En­dothelial Growth Factor). VEGF increases the per­meability and dilation of endometrial blood vessels which play an important role in imp­lan­ta­tion. This study aimed to analyze the difference of VEGF expression between women with PCOS and nor­mal women. Subjects and Method: This study was a case-con­trol study design conducted at the polyclinic of the Department of Obstetrics and Gynecology, Dr. Moewardi Hospital, Surakarta, Central Java, in July 2020. There were 30 infertile women with PCOS (diagnosis based on Rotterdam criteria, con­sensus 2003) and 30 women without PCOS as the sample of this study. The dependent variable was VEGF expression. The independent variables were age, BMI, family history with PCOS, menar­che, occu­pa­tion, and education. VEGF expression was ob­tained from an endometrial biopsy on days 19-24 of periods. The differences in VEGF exp­res­sion (in %) were analyzed by the Mann-Whitney test. VEGF determinants were analyzed by a mul­ti­ple linear regression. Results: The mean of VEGF expression in wo­men with PCOS (Mean=64.33; SD=44.43) was high­er than in women without PCOS (Mean­= 7.90; SD=8.73) and the result was statistically sig­ni­ficant (p<0.001). PCOS (b=42.09; 95%­CI­=­64.­2­6 to -19.93; p<0.001) and obese (b=38.63; 95%­CI=-63.44 to -13.82; p=0.003) increased VEGF expression. Conclusion: VEGF expression in the endo­met­rium of women with PCOS is higher than normal wo­men. Keyword s : VEGF, endometrium, Polycystic Ova­rian Syndrome Correspondence: Ricky Bernadi Saputra. Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sebe­las Maret/ Dr. Moewardi Hospital, Sura­karta, Indo­nesia. Telp: 081221161933 Email: ricky­sa­put­radr@gmail.com Indonesian Journal of Medicine (2020), 05(03): 230-239 https://doi.org/10.26911/theijmed.2020.05.03.08

Evaluation of apoptosis and hypoxia-related factors in gingival tissues of smoker and non-smoker periodontitis patients.

Smoking causes pathological changes in all tissues, including gingiva and alveolar bone. The aim of present study was to evaluate apoptotic tissue alterations and tissue destruction in smoker and non-smoker periodontitis patients and healthy individuals. Gingival biopsy samples from 15 systemically and orally healthy individuals (Group 1), 15 systemically healthy periodontitis patients (Group 2), 15 systemically and orally healthy smokers (Group 3), and 15 systemically healthy smoker periodontitis patients (Group 4) were enrolled in the present study. Clinical periodontal measurements as plaque index (PI), gingival index (GI), and clinical attachment levels (CAL) were recorded, and gingival biopsies were obtained. Biopsy samples were fixed in formalin solution and embedded in paraffin. Fibroblast and inflammatory cell counts were determined via histomorphometrically. Hypoxia-inducible factor alpha (HIF-1α), vascular endothelial growth factor(VEGF), tissue inhibitor of matrix metalloproteinase-1(TIMP-1), matrix metalloproteinases-8(MMP-8) expressions, Bax, Bcl-2, and caspase-3 expressions were evaluated via immunohistochemistry. Demographic data of the study groups were similar. Smoking levels of the smokers were also similar. The highest fibroblast cell counts were observed in healthy controls and the counts were similar in other groups. The highest inflammatory cell counts were found in smoker periodontitis group, and the lowest counts were found in healthy control groups. The differences were statistically significant. HIF-1α and Bax expressions were elevated and Bcl-2 decreased in smoker periodontitis patients compared with healthy individuals. However, there were no differences in VEGF, MMP-8, and TIMP-1 expressions. Within limits of present study, it can be suggested that both smoking and periodontitis caused similar decrease in fibroblast counts while causing a dramatic increase in inflammatory cell counts. Increased apoptosis and hypoxia also accompanied to the increased inflammation.

Poziom cytokin IL-35, TNF-α, BAFF i VEGF w surowicy w różnych chorobach reumatycznych.

ObjectivesInflammatory processes in rheumatic diseases spread via various types of immune system cells and tissues with the aid of inflammatory cytokines and growth factors and the participation of vascular endothelium. Research is still conducted to determine the role of individual factors in the pathophysiology of rheumatic diseases. The task is complicated because the multiplane network of cytokines is characterized by complex correlations manifesting as positive and negative feedback, which impedes the definitive interpretation of the role of specific cytokines. Therefore, it seems justified to perform a comparative analysis of the expression of at least several molecules in one study, which may help reveal their role in the pathogenesis of rheumatic diseases and have prognostic value.Material and methodsThe aim of the study involves the assessment and comparative analysis of the concentrations of interleukin 35 (IL-35), tumour necrosis factor α (TNF-α), B-cell-activating factor (BAFF), and vascular endothelial growth factor (VEGF) in peripheral blood serum in patients with rheumatoid arthritis (RA) (n = 43), systemic lupus erythematosus (SLE) (n = 28), antiphospholipid syndrome (APS) (n = 24), and mixed connective tissue disease (MCTD) (n = 9). The main intention is to search for biomarkers for specific rheumatic diseases. Cytokine and growth factor levels were determined using specific ELISA kits.ResultsStatistically significant differences in VEGF and IL-35 concentrations occurred between patients with APS vs. RA and SLE vs. RA. There was a significant high positive correlation between the concentration of BAFF and TNF-α (r = 0.77, p < 0.0000) in patients with APS, as well as in patients with SLE (r = 0.55, p = 0.00).ConclusionsBAFF and TNF-α may be promising biomarkers in patients with APS and VEGF in patients with RA. Additionally, IL-35 may be a useful marker for the diagnosis of APS. Positive correlation of BAFF and TNF-α concentrations in APS and SLE potentially indicates much more similar etiopathogenesis of these diseases than it could be previously predicted.

Effect of Prenatal Vitamin D Supplementation on Placental Angiogenic Factors in Bangladesh (FS08-07-19)

ObjectivesTo determine the effect of prenatal vitamin D supplementation on expression of angiogenic factors in the placenta. MethodsThis is a secondary analysis of the Maternal Vitamin D for Infant Growth trial, a randomized controlled trial of maternal vitamin D supplementation in Dhaka, Bangladesh. We examined the expression of angiogenic factors in placental tissues. Women (n = 1300) were enrolled at 17–24 weeks gestation and randomized to receive: placebo, 4200 IU/week, 16,800 IU/week or 28,000 IU/week until delivery. We examined a subset of randomly selected placentas (n = 80) collected at birth, which included 20 tissues (10 male & 10 female offspring) from each treatment group in maternal/fetal pairs. A full thickness placental core was collected; fixed in formalin and embedded in paraffin. Tissue sections were stained for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) using immunofluorescence. ImageJ was used to quantify intensity and % area of expression. T-tests were used to estimate the effects of each vitamin D dose on expression of angiogenic factors, compared to placebo. Interactions by fetal sex were also examined. ResultsThe mean (SD) for % area of expression was 17.0 (4.0) for VEGF and 14.8 (1.9) for PlGF. The mean (SD) for intensity was 6520 (1549) for VEGF and 5716 (734) for PlGF. There were no significant differences in VEGF and PlGF between any vitamin D treatment groups versus placebo for % area or intensity of expression (Table 1). The effect of vitamin D treatment was not modified by fetal sex. ConclusionsVitamin D supplementation starting from mid-pregnancy until delivery did not effect expression of two key angiogenic factors in the placenta at term. The impact of periconception vitamin D supplementation on expression of angiogenic factors in the placenta remains unknown. Funding SourcesBill and Melinda Gates Foundation. Supporting Tables, Images and/or Graphs▪

Post-weaning social isolation of rats induces reduction in the gene expression of vascular endothelial growth factor (VEGF) in the hippocampus.

The role of vascular endothelial growth factor (VEGF) in chronic stress and neurodevelopmental disorders is of growing research interest. Here we show that post-weaning isolation rearing of rats decreased gene expression of VEGF in the hippocampus. Gene expression of VEGF upstream regulator fibroblast growth factor-2 (FGF-2) or its downstream mediator endothelial nitric oxide synthase (eNOS) was unchanged. Other signaling pathways appear to be involved in isolation-induced reduction in VEGF gene expression. Sex differences in VEGF and eNOS gene expression with significantly higher mRNA levels in females than males were revealed.

Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in children with brain tumors.

Angiogenesis is the process of new vessel formation originating from the existing vascular network. It plays an important role in the growth and spread of malignancies, including brain tumors. The process of angiogenesis is characterized by increased expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and by the release of their soluble forms into circulation. The aim of the study was to evaluate serum levels of VEGF and bFGF in children with malignant and benign brain tumors. The study group (group N) included 106 children diagnosed with brain tumors. The children in group N were classified according to tumor pathology into 3 subgroups: N1 (n = 63): patients with malignant tumors, excluding anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM); N2 (n = 25): patients with benign tumors; and N3 (n = 18): patients with high grade gliomas (AA and GBM). VEGF and bFGF were determined by ELISA in blood samples before the initiation of chemotherapy. VEGF and bFGF levels were compared within the subgroups in relation to tumor grading and the extent of surgery. The median VEGF in patients with brain tumors was significantly higher than in the control group. The median levels of VEGF and bFGF in subgroup N1 were significantly higher than in the control group. The differences in VEGF and bFGF concentrations between the subgroups in relation to the extent of tumor resection were not significant. Significantly higher plasma VEGF levels in children with brain neoplasms may reflect enhanced angiogenesis in the tumors.

Extraocular motoneurons of the adult rat show higher levels of vascular endothelial growth factor and its receptor Flk-1 than other cranial motoneurons.

Recent studies show a relationship between the deficit of vascular endothelial growth factor (VEGF) and motoneuronal degeneration, such as that occurring in amyotrophic lateral sclerosis (ALS). VEGF delivery protects motoneurons from cell death and delayed neurodegeneration in animal models of ALS. Strikingly, extraocular motoneurons show lesser vulnerability to neurodegeneration in ALS compared to other cranial or spinal motoneurons. Therefore, the present study investigates possible differences in VEGF and its main receptor VEGFR-2 or Flk-1 between extraocular and non-extraocular brainstem motoneurons. We performed immunohistochemistry and Western blot to determine the presence of VEGF and Flk-1 in rat motoneurons located in the three extraocular motor nuclei (abducens, trochlear and oculomotor) and to compare it to that observed in two other brainstem nuclei (hypoglossal and facial) that are vulnerable to degeneration. Extraocular motoneurons presented higher amounts of VEGF and its receptor Flk-1 than other brainstem motoneurons, and thus these molecules could be participating in their higher resistance to neurodegeneration. In conclusion, we hypothesize that differences in VEGF availability and signaling could be a contributing factor to the different susceptibility of extraocular motoneurons, when compared with other motoneurons, in neurodegenerative diseases.

The Morphofunctional Changes in the Wall of Varicose Veins

Varicose vein (VV) disease is a frequently occurring pathology of the lower extremities. Although the pathogenesis of varicosity development is not clearly defined, the final common pathway leading to chronic venous insufficiency is the development of venous hypertension, which is associated with severe changes in the venous wall. The aim of this study was to clarify the histological and immunohistochemical changes in great saphenous veins (GSVs) in chronic venous insufficiency. A histopathological study was conducted on 20 patients with VVs (4 males, 16 females) and 4 (1 male, 3 females) patients undergoing distal bypass surgery. Tissues were processed for histological routine straining and immunohistochemical studies of vascular endothelial growth factor (VEGF), intercellular adhesion molecule (ICAM)-1, vascular adhesion molecule (VCAM)-1, protein gene product 9.5 (PGP 9.5), and collagen type IV, laminin, and fibronectin. A semiquantitative evaluation method was used. Compared with the normal SV, VV sections showed the damaged endothelium areas, significant disorganization of the smooth muscle bundles, and highest density of the vasa vasorum in the tunica media and tunica adventitia, as well as sclerotic blood vessels and neoangiogenesis in almost all specimens. Immunohistochemistry study showed statistically significant difference between the VVs and the control group of several parameters, such as PGP 9.5 positive structures (P<0.05; 1-tailed significance) and laminin positive structures in subendothelial layer of VVs (P<0.05; 1-tailed significance). There is also the tendency in increasing of VEGF expression and decreasing of collagen IV structures. Our study did not show statistically significant difference in VEGF, ICAM-1, and VCAM-1 positive structures between varicose and normal veins; however, it could be explained by the limitations of the study. Varicose GSVs represent nonhomogeneous integrity of the basement membrane, smooth muscle disorganization, and active neoangiogenesis, suggesting remodulation of blood vessels. Changes in the appearance of PGP 9.5-containing innervation, laminin, and collagen IV in tunica intima confirm the remodulation of damaged blood vessels.

Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.

BackgroundRapidly growing cancer cells secrete growth-promoting polypeptides and have increased proteolytic activity, contributing to tumor progression and metastasis. Their presentation in malignant pleural effusion (MPE) and their predictive value for the outcome of pleurodesis and survival were studied.MethodsBetween February 2011 and March 2012, MPE samples were prospectively collected from 61 patients. Twenty-five patients with non-malignant pleural effusion in the same period were included as controls. Pleural fluid osteopontin (OPN), vascular endothelial growth factor (VEGF), and urokinase-type plasminogen activator (uPA) concentrations were measured.ResultsPatients with MPE had higher pleural fluid OPN, VEGF, and uPA concentrations than those with non-malignant pleural effusion, but only differences in VEGF were statistically significant (p = 0.045). Patients with distant metastases had significantly elevated pleural fluid VEGF concentrations than those without (p = 0.004). Pleural fluid OPN, VEGF, and uPA concentrations were positively correlated in most patients. However, there was no significant difference in pleural fluid OPN, VEGF, and uPA concentrations between patients with successful pleurodesis and those without. There was also no significant difference in cancer-specific survival between sub-groups with higher and lower pleural fluid OPN, VEGF, or uPA concentrations. Patients with successful pleurodesis had significantly longer cancer-specific survival than those without (p = 0.015).ConclusionsPleural fluid OPN, VEGF, and uPA concentrations are elevated in MPE but are not satisfactory predictors of pleurodesis outcome or survival. Patients with higher pleural fluid VEGF concentration have higher risk of distant metastasis. Evaluating the benefits of therapy targeting the VEGF pathway in these patients warrants further studies.

The relationship between the expression of VEGF, EGFR, and HER-2 mRNA in esophageal squamous cell carcinoma (ESCC) and clinicopathological features of different ethnic groups in Xinjiang.

The purpose of this study was to explore the relationship between the expression of vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (HER-2), and epidermal growth factor receptor (EGFR) mRNA in esophageal squamous cell carcinoma (ESCC) and the clinicopathological characteristics of the Han, Uyghur, and Kazakh in Xinjiang. Real-time quantitative polymerase chain reaction technology (RT-PCR) was used to detect the expression of VEGF, HER-2, and EGFR mRNA in esophageal squamous cancer tissue of 60 cases and 30 cases of VEGF, HER-2, and EGFR mRNA in esophageal cancer adjacent tissues, and analyze its relationship with clinicopathological features. The results were as follows: (1) There was no statistically significant difference in esophageal tissue VEGF, HER-2, and EGFR mRNA gene expression levels of the Han, Uyghur, and Kazakh patients (P > 0.05). (2) The expression levels of VEGF, HER-2, and EGFR mRNA in ESCC group were higher than those in adjacent esophageal tissue group (P < 0.05). (3) The expression levels of VEGF and HER-2 mRNA in ESCC of the Han patients were higher than those of the Uyghur and Kazakh patients (P < 0.05). (4) The expression levels of VEGF, HER-2, and EGFR mRNA in lymph node metastases were higher than those without lymph node metastasis (P < 0.05). (5) The expression level of HER-2 mRNA was related with the degrees of pathological differentiation, and the higher pathologic degree, the lower expression level in HER-2 mRNA (P < 0.05). Therefore, the following conclusions were drawn: (1) There were ethnic differences in the VEGF and HER-2 gene mRNA expression levels of the Uyghur, Han, and Kazakh patients in Xinjiang. (2) The expressions of VEGF, HER-2, and EGFR mRNA were related to the lymph node metastasis in ESCC and pathologic differentiation degree.

The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome.

This research investigated the response of vascular active factors, vascular endothelial growth factor (VEGF) and angiotensin-II (AT-II) to ovarian stimulation during 24 hours in patients with polycystic ovary syndrome (PCOS). In this clinical trial study, 52 patients with PCOS and 8 control cases were stimulated with human chorionic gonadotropin (HCG) on the 4(th) to 7(th) day of the patients' natural or induced menstrual cycles. We measured VEGF and AT-II by radioimmunoassay before the injection (0 hour) and 3, 8, 12, 18 and 24 hours after the stimulation. After ovarian stimulation, there was substantially higher level of VEGF in typical PCOS patients than the other three groups at the 3 hour time point (p<0.05), while there were no significant differences in VEGF at all the other time points among the four groups. As for AT-II, before and at all time points after the ovarian stimulation, it seemed that the AT-II levels in patients' sera with different phenotypes of PCOS by the Rotterdam criteria were all higher than in the control group although the differences were not statistically significant. The level of AT-II in typical PCOS patients was also significantly higher than the other three groups at the 3 hour time point (p<0.05), while no significant differences at all the other time points among the four groups were observed. The response to the stimulation varied among patients with different phenotypes of PCOS according to the Rotterdam criteria. Serum VEGF and AT-II were possible contributors to an increased risk of developing ovarian hyperstimulation syndrome (OHSS) in patients with typical PCOS during the early follicular phase (3 hours) after ovarian stimulation ( NCT02265861).

Aging and the Skeletal Muscle Angiogenic Response to Exercise in Women.

Whether aging lowers skeletal muscle basal capillarization and angiogenesis remains controversial. To investigate the effects of aging on skeletal muscle capillarization, eight young (YW) and eight aged (AW) women completed 8 weeks of exercise training. The response and relationships of muscle capillarization, interstitial vascular endothelial growth factor (VEGF), and microvascular blood flow to aerobic exercise training were investigated. Vastus lateralis biopsies were obtained before and after exercise training for the measurement of capillarization. Muscle interstitial VEGF protein and microvascular blood flow were measured at rest and during submaximal exercise at PRE, 1-WK, and 8-WKS by microdialysis. Exercise training increased (20%-25%) capillary contacts of type I, IIA, and IIB fibers in YW and AW. Interstitial VEGF protein was higher in AW than YW at rest and was higher in YW than AW during exercise independent of training status. Differences in muscle capillarization were not explained by secreted VEGF nor were differences in VEGF explained by microvascular blood flow. These results confirm that aging (57-76 years age range) does not impair the muscle angiogenic response to exercise training, although sex differences may exist in similarly trained women and men.